GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Debt-to-EBITDA

ProKidney (ProKidney) Debt-to-EBITDA : -0.06 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProKidney's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.80 Mil. ProKidney's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.61 Mil. ProKidney's annualized EBITDA for the quarter that ended in Dec. 2023 was $-71.14 Mil. ProKidney's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ProKidney's Debt-to-EBITDA or its related term are showing as below:

PROK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06   Med: -0.03   Max: -0.02
Current: -0.04

During the past 4 years, the highest Debt-to-EBITDA Ratio of ProKidney was -0.02. The lowest was -0.06. And the median was -0.03.

PROK's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.355 vs PROK: -0.04

ProKidney Debt-to-EBITDA Historical Data

The historical data trend for ProKidney's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Debt-to-EBITDA Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.06 -0.03 -0.02 -0.04

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.06

Competitive Comparison of ProKidney's Debt-to-EBITDA

For the Biotechnology subindustry, ProKidney's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProKidney's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ProKidney's Debt-to-EBITDA falls into.



ProKidney Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProKidney's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.803 + 3.61) / -125.586
=-0.04

ProKidney's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.803 + 3.61) / -71.136
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


ProKidney  (NAS:PROK) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ProKidney Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ProKidney's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (ProKidney) Business Description

Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Executives
Chamath Palihapitiya 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton officer: EVP, Clinical Development 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen 10 percent owner 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger officer: Chief People Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle director
Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403